Molecular Partner…
CHCHFMolecular Partners AG (US:MLLCF) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- molecularpartners.com
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège Social
- Schlieren-Zurich, Switzerland
- PDG
- Patrick Amstutz
- Employés
- 134
- Actions en Circulation
- 38.31 M
- Flottant
- 20.71 M
- Capitalisation Boursière
- 127.56 M CHF
- Initiés
- 8.47%
- Investisseurs Institutionnels
- 43.8%
- Secteur d'Activité (SIC)
- Biological Products, (No Diagnostic Substances)
- Forme Juridique
- MVII
- ISIN
- US60853G1067
- LEI
- 875500AXMLDAZ4D21744
- FCF
- −52.0 M CHF
- Dette
- ?
- Résultats et FCF — pour les 12 mois à 31.12.2025 (dernier rapport de l'entreprise).
Description
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| Old Mission Capital, LLC | 0.03% | 11 347 | 2025-06-30 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 923 | 2026-07-31 |
| DFA INVESTMENT DIMENSION… | 0.01% | 3 503 | 2026-07-31 |
| American Century ETF Tru… | 0% | 12 | 2026-08-31 |
